Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Registered patient at MSKCC
Age ≥18 years
Patients with HER2+ metastatic breast cancer (either 3+ by immunohistochemistry or with evidence of gene amplification (\>2.0) by fluorescence in situ hybridization (FISH))
Measurable or evaluable disease
Currently taking or about to commence treatment with trastuzumab at a dosing schedule of 2 mg/kg weekly or 6 mg/kg every three weeks, as per standard of care
Karnofsky Performance Score ≥ 60
Signed informed consent
You may not be if
Previous Grade 3 or higher allergic reaction to trastuzumab that resulted in discontinuation of trastuzumab therapy
Claustrophobia/pain leading to inability to lie still for the duration of the scanning procedure.
Pregnancy Test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material.
Inability to provide written informed consent.
Patients with liver metastases as the only site of distant disease
Patients with known sensitivity or contraindication to Herceptin.
Clareo Health | PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
